Meeting
2015 ASCO Annual Meeting
Evaluation of the Breast Cancer Index in patients with HER2+/HR+ breast cancer for risk of late recurrence and potential extended endocrine benefit.
Authors
Ruth O'Regan
Emory Univ, Atlanta, GA
Ruth O'Regan , Brock Schroeder , Nichole Renee Blatner , Catherine A. Schnabel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 595)
DOI
10.1200/jco.2015.33.15_suppl.595
Abstract #
595
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.
First Author: Federico Rojo
Poster
2011 ASCO Annual Meeting
Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).
First Author: P. Ravdin
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2023 ASCO Annual Meeting
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
First Author: Rebecca Arielle Shatsky